Topics

SunLink Health Systems, Inc. Announces Fiscal 2020 Second Quarter Results

16:24 EST 13 Feb 2020 | Businesswire
SunLink Health Systems, Inc.

SunLink Health Systems, Inc. (NYSE American: SSY) today announced earnings from continuing operations of $203,000 ($0.03 per fully diluted share) for its second fiscal quarter ended December 31, 2019 compared to earnings of $258,000, ($0.04 per fully diluted share) for the quarter ended December 31, 2018. Net loss for the quarter ended December 31, 2019 was $42,000 (or a loss of $0.01 per fully diluted share) compared to net earnings of $305,000 ($0.04 per fully diluted share) for the quarter ended December 31, 2018.

During the quarters ended December 31, 2019 and 2018, the Company reported the following items:

 

Quarters ended

December 31,

2019

 

2018

Prior year cost report settlement in the Healthcare Services segment    $   107,000

$

(15,000

)

Revenue from amended sales tax returns and accruals in the Pharmacy segment

 

267,000

 

 

0

 

Gain on sale of assets  

 

86,000

 

 

452,000

 

Loss on early extinguishment of debt

 

   (160,000

)

 

 

0

 

 

Consolidated net revenues from continuing operations for the quarters ended December 31, 2019 and 2018 were $12,805,000 and $12,151,000, respectively, an increase of 5% in the current fiscal year’s second quarter compared to the comparable quarter of the prior fiscal year. Net revenues increased in the current fiscal quarter primarily due to increased nursing home net revenues and the prior year cost report settlements in the Healthcare Services segment, and increased Pharmacy segment revenues, including the amended sales tax accrual in the Pharmacy segment.

SunLink reported an operating profit for the quarter ended December 31, 2019 of $281,000, compared to an operating loss for the quarter ended December 31, 2018 of $134,000.

Loss from discontinued operations was $245,000 (or a loss of $0.04 per fully diluted share) for the quarter ended December 31, 2019 compared to earnings from discontinued operations of $47,000 ($0.01 per fully diluted share) for the quarter ended December 31, 2018. Results from discontinued operations in the current year include expenses incurred in connection with retained professional liability claims and workers compensation claims associated with sold businesses as well as settlement of a lawsuit relating to one such business.

SunLink had approximately 4% fewer fully diluted weighted average common shares outstanding for the three months ended December 31, 2019 compared to the comparable quarter last year due to share repurchases in December 2018.

For the six months ended December 31, 2019, SunLink reported earnings from continuing operations of $60,000 ($0.01 per fully diluted share) compared to a loss from continuing operations of $528,000 (or a loss of $0.07 per fully diluted share) for the six months ended December 31, 2018. For the six months ended December 31, 2019, SunLink reported a net loss of $303,000 (or a loss of $0.04 per fully diluted share) compared to a net loss of $575,000 (or a loss of $0.08 per fully diluted share) for the six months ended December 31, 2018. Loss from discontinued operations were $363,000 (or a loss of $0.05 per fully diluted share) for the six months ended December 31, 2019 compared to a loss from discontinued operations of $47,000 (or a loss of $0.01 per fully diluted share) for the six months ended December 31, 2018.

SunLink Health Systems, Inc. is the parent company of subsidiaries that own and operate healthcare properties and businesses in the Southeast. Each of the Company’s businesses is operated locally with a strategy of linking patients’ needs with healthcare professionals. For additional information on SunLink Health Systems, Inc., please visit the Company’s website.

This press release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the company’s business strategy. These forward-looking statements are subject to certain risks, uncertainties and other factors, which could cause actual results, performance and achievements to differ materially from those anticipated. Certain of those risks, uncertainties and other factors are disclosed in more detail in the company’s Annual Report on Form 10-K for the year ended June 30, 2019 and other filings with the Securities and Exchange Commission which can be located at www.sec.gov.

 
 
 
 

SUNLINK HEALTH SYSTEMS, INC. ANNOUNCES

FISCAL 2020 SECOND QUARTER RESULTS

Amounts in 000's, except per share and volume amounts

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CONSOLIDATED STATEMENTS OF EARNINGS (LOSS)  

 

 Three Months Ended December 31, 

 

 Six Months Ended December 31, 

 

2019

 

2018

 

2019

 

2018

 

 

 

% of Net

 

 

 

% of Net

 

 

 

% of Net

 

 

 

% of Net

 

Amount

 

Revenues

 

Amount

 

Revenues

 

Amount

 

Revenues

 

Amount

 

Revenues

Net Revenues

 $

         12,805

 

 

100.0

%

 $

  12,151

 

100.0

%

 $

  24,457

 

100.0

%

 $

  22,358

 

100.0

%

Costs and Expenses:
Cost of goods sold

 

             5,097

 

 

39.8

%

 

      5,255

 

43.2

%

 

      9,441

 

38.6

%

 

      9,172

 

41.0

%

Salaries, wages and benefits

 

             4,849

 

 

37.9

%

 

      4,620

 

38.0

%

 

      9,758

 

39.9

%

 

      9,294

 

41.6

%

Supplies

 

                334

 

 

2.6

%

 

         324

 

2.7

%

 

         653

 

2.7

%

 

         612

 

2.7

%

Purchased services

 

                753

 

 

5.9

%

 

         585

 

4.8

%

 

      1,456

 

6.0

%

 

      1,154

 

5.2

%

Other operating expenses

 

                994

 

 

7.8

%

 

         982

 

8.1

%

 

      2,097

 

8.6

%

 

      1,995

 

8.9

%

Rents and leases

 

                147

 

 

1.1

%

 

         168

 

1.4

%

 

         306

 

1.3

%

 

         303

 

1.4

%

Depreciation and amortization

 

                350

 

 

2.7

%

 

         351

 

2.9

%

 

         685

 

2.8

%

 

         689

 

3.1

%

Operating Profit (Loss )

 

                281

 

 

2.2

%

 

        (134

)

-1.1

%

 

           61

 

0.2

%

 

        (861

)

-3.9

%

 
Interest Expense - net

 

                  (4

)

 

0.0

%

 

          (60

)

-0.5

%

 

          (34

)

-0.1

%

 

        (121

)

-0.5

%

Loss on extinguishment of debt,  net

 

(160

)

 

-1.2

%

 

0

 

0.0

%

 

(160

)

-0.7

%

 

0

 

0.0

%

Gains on sale of assets

 

                  86

 

 

0.7

%

 

         452

 

3.7

%

 

         193

 

0.8

%

 

         454

 

2.0

%

 
Earnings (Loss) from Continuing Operations before Income Taxes

203

1.6

%

258

2.1

%

60

0.2

%

(528

)

-2.4

%
Income Tax expense (benefit)

 

0

 

 

0.0

%

 

0

 

0.0

%

 

0

 

0.0

%

 

0

 

0.0

%

Earnings (Loss) from Continuing Operations 

 

                203

 

 

1.6

%

 

         258

 

2.1

%

 

           60

 

0.2

%

 

        (528

)

-2.4

%

Earnings (Loss) from Discontinued Operations, net of tax

 

               (245

)

 

-1.9

%

 

           47

 

0.4

%

 

        (363

)

-1.5

%

 

          (47

)

-0.2

%

Net Earnings  (Loss)

 $

              (42

)

 

-0.3

%

 $

      305

 

2.5

%

 $

     (303

)

-1.2

%

 $

     (575

)

-2.6

%

Earnings (Loss)  Per Share from Continuing Operations:
    Basic 

 $

            0.03

 

 $

     0.04

 

 $

     0.01

 

 $

    (0.07

)

    Diluted

 $

            0.03

 

 $

     0.04

 

 $

     0.01

 

 $

    (0.07

)

Earnings (Loss) Per Share from Discontinued Operations:
    Basic 

 $

           (0.04

)

 $

     0.01

 

 $

    (0.05

)

 $

    (0.01

)

    Diluted

 $

           (0.04

)

 $

     0.01

 

 $

    (0.05

)

 $

    (0.01

)

Net Earnings (Loss) Per Share:
    Basic 

 $

           (0.01

)

 $

     0.04

 

 $

    (0.04

)

 $

    (0.08

)

    Diluted

 $

           (0.01

)

 $

     0.04

 

 $

    (0.04

)

 $

    (0.08

)

Weighted Average Common Shares Outstanding:
    Basic 

 

             6,986

 

 

      7,271

 

 

      6,986

 

 

      7,309

 

    Diluted

 

             6,992

 

 

      7,278

 

 

      7,012

 

 

      7,309

 

 
HEALTHCARE FACILITIES VOLUME STATISTICS
 
Hospital and Nursing Home Admissions

 

                  97

 

 

         129

 

 

         220

 

 

         243

 

Hospital and Nursing Home Patient Days

 

             6,890

 

 

      6,768

 

 

     13,851

 

 

     13,198

 

 
SUMMARY BALANCE SHEETS

December 31,

 

June 30,

2019

 

2019

ASSETS
Cash and Cash Equivalents

 $

          4,607

 

 $

    7,742

 

Accounts Receivable - net

 

             5,627

 

 

       4,715

 

Other Current Assets

 

             4,150

 

 

       4,201

 

Property Plant and Equipment, net

 

             5,412

 

 

       5,243

 

Long-term Assets

 

             3,027

 

 

       2,518

 

   

 $

         22,823

 

 $

  24,419

 

LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities

 $

          6,440

 

 $

    8,410

 

Long-term Debt and Other Noncurrent Liabilities

 

             1,621

 

 

         966

 

Shareholders' Equity

 

           14,762

 

 

     15,043

 

 $

         22,823

 

 $

  24,419

 

 
 

 

 

Robert M. Thornton, Jr.
Chief Executive Officer
(770) 933-7004

NEXT ARTICLE

More From BioPortfolio on "SunLink Health Systems, Inc. Announces Fiscal 2020 Second Quarter Results "

Quick Search

Relevant Topics

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...